Clinical Trial Search

Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019

Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01

Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197

Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity

Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99

Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale

Primary: Overall Response Rate — 3; 6 eyes — p=0.375

Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants

Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants

Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…

Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373

Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants

Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants

Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects

Primary: Feasibility of Enrolling Patients — 21 Participants

Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants

Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Significant Clinical Response — 9; 10 participants

Primary: Intraocular Pressure — 11; 27 eyes

Primary: Graft Size Change — 10 percent change in graft

Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients

Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants

Primary: Participants That Developed Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease (GVHD). — 7; 4 Participants

Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline